Progena Biopharma

Progena Biopharma is a Swiss biotechnology company dedicated to developing transformative therapies for degenerative retinal diseases. Founded by a team of industry veterans and academic experts from the University of Geneva, the company focuses on haploinsufficient conditions where boosting the expression of the remaining functional gene can halt disease progression. Its lead program targets Retinitis Pigmentosa 11 (RP11) by using small molecules to increase the expression of the PRPF31 gene. Progena’s approach leverages high-throughput screening and deep expertise in RNA splicing and genetics to address unmet needs in blindness-causing conditions. The company is currently advancing its pipeline through pre-clinical development, aiming to provide disease-modifying treatments for orphan indications that lack effective pharmacological options.